Darolutamide Plus Hormone Therapy for Prostate Cancer in China
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study watches how well a drug called darolutamide works when combined with hormone therapy for men with prostate cancer that has returned after previous treatment. The goal is to understand if this combination helps prevent cancer spread and is safe to use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 18 or older
- Your prostate cancer came back after at least 6 months of hormone therapy plus bicalutamide (a prior prostate cancer drug)
- You have no signs of cancer spread to other parts of your body (confirmed by imaging scans)
- Your testosterone level is very low (below 1.7 nmol/L), showing hormone therapy is working
- Your doctor has decided to treat you with hormone therapy plus darolutamide as part of routine care
- You are in good enough health to participate (ECOG score 0 or 1, meaning you can do most normal activities)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how safe darolutamide is and how well it works when added to standard hormone therapy for men with high-risk, non-metastatic prostate cancer that is no longer responding to hormone treatment. It may help slow prostate cancer growth and reduce prostate-specific antigen (PSA) rises in real-world care.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
This study looks at combining a drug called darolutamide with standard hormone therapy for men whose prostate cancer has spread to the lymph nodes after surgery. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests a combination of two drugs (darolutamide plus hormone therapy) along with a low dose of chemotherapy (docetaxel) for men whose prostate cancer has spread to other parts of the body. It aims to see if this combined approach is safe and effective.
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
Hear when a new Non-metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.